Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:TNXP 16 August 2025 - 7 December 2025

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals’ stock surged over 10,000% in the past year after FDA approval and U.S. launch of its fibromyalgia drug Tonmya, the first new therapy for the condition in over 15 years. TNXP closed at $19.64 on December 5, with a market cap near $200 million and high volatility. Short interest stands at 16.5%. The company is also testing the drug for major depressive disorder.
7 December 2025
··
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals’ stock (NASDAQ: TNXP) closed near $19.98 on December 4, 2025, up roughly 10–12% for the day and about 10,515% over the past year. The surge follows FDA approval and U.S. launch of Tonmya, the first new fibromyalgia drug in over 15 years. Market cap stands near $190 million. Investors remain focused on whether Tonmya sales can offset heavy cash burn and potential dilution.
4 December 2025
··
TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

Tonix Pharmaceuticals shares fell 11% to close at $14.29 on Monday, despite receiving FDA clearance to advance its depression drug TNX-102 SL into Phase 2 trials. The stock sits near the bottom of its 52-week range after sharp volatility and recent expansion of its at-the-market stock offering program. Tonix recently launched Tonmya for fibromyalgia and reported $190.1 million in cash for Q3 2025.
25 November 2025
·
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals’ first commercial fibromyalgia drug, Tonmya, is now available in U.S. pharmacies following FDA approval in August. TNXP shares closed Friday at $16.10, up 2.94%, but remain down about 51% for 2025. Market cap stands near $141 million, with negative net margins and a price-to-sales ratio of 13.7. Expanded share repurchase and ATM equity programs are in place.
23 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Go toTop